Bessemer Group Inc. Raises Position in DexCom, Inc. (NASDAQ:DXCM)

Bessemer Group Inc. lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 2.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,040,093 shares of the medical device company’s stock after purchasing an additional 25,061 shares during the quarter. Bessemer Group Inc. owned about 0.27% of DexCom worth $133,663,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Avalon Trust Co bought a new stake in DexCom in the first quarter worth about $26,000. Atlas Capital Advisors LLC purchased a new position in DexCom during the 2nd quarter valued at $33,000. TFC Financial Management Inc. grew its position in DexCom by 4,814.3% in the 1st quarter. TFC Financial Management Inc. now owns 344 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 337 shares during the last quarter. Valley National Advisers Inc. grew its position in DexCom by 33.5% in the 2nd quarter. Valley National Advisers Inc. now owns 379 shares of the medical device company’s stock valued at $49,000 after acquiring an additional 95 shares during the last quarter. Finally, Center for Financial Planning Inc. purchased a new stake in DexCom in the second quarter worth $51,000. Institutional investors own 93.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Raymond James reduced their price target on shares of DexCom from $154.00 to $131.00 and set a “strong-buy” rating on the stock in a research note on Friday, September 15th. Oppenheimer boosted their price target on DexCom from $135.00 to $150.00 in a report on Friday, July 28th. Stifel Nicolaus dropped their price objective on DexCom from $155.00 to $145.00 and set a “buy” rating on the stock in a research note on Tuesday, October 10th. Citigroup decreased their target price on DexCom from $150.00 to $115.00 in a research report on Monday, October 2nd. Finally, Robert W. Baird cut their price target on DexCom from $153.00 to $130.00 and set an “outperform” rating on the stock in a research note on Monday, August 21st. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.93.

Insider Transactions at DexCom

In related news, Director Steven R. Altman sold 1,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $101.26, for a total value of $101,260.00. Following the completion of the transaction, the director now owns 59,700 shares of the company’s stock, valued at approximately $6,045,222. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Barry J. Regan sold 2,019 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $95.22, for a total value of $192,249.18. Following the completion of the transaction, the executive vice president now directly owns 64,250 shares of the company’s stock, valued at approximately $6,117,885. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Steven R. Altman sold 1,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $101.26, for a total transaction of $101,260.00. Following the sale, the director now directly owns 59,700 shares of the company’s stock, valued at approximately $6,045,222. The disclosure for this sale can be found here. Insiders have sold a total of 6,908 shares of company stock valued at $657,820 in the last ninety days. 0.41% of the stock is currently owned by corporate insiders.

DexCom Trading Up 3.8 %

Shares of NASDAQ:DXCM opened at $108.96 on Tuesday. The business has a 50-day moving average price of $91.06 and a 200-day moving average price of $109.71. The stock has a market cap of $42.10 billion, a price-to-earnings ratio of 119.74, a PEG ratio of 2.13 and a beta of 1.13. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $139.55. The company has a quick ratio of 2.50, a current ratio of 2.80 and a debt-to-equity ratio of 1.07.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 26th. The medical device company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.34 by $0.16. DexCom had a net margin of 11.08% and a return on equity of 25.05%. The business had revenue of $975.00 million during the quarter, compared to analysts’ expectations of $939.64 million. During the same period in the previous year, the business posted $0.28 EPS. The business’s quarterly revenue was up 26.7% compared to the same quarter last year. Equities analysts predict that DexCom, Inc. will post 1.43 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.